2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-134006
    Stemoninine 69772-72-1 98%
    Stemoninine is a lycoris alkaloid that can be used as an antitussive. Stemoninine has significant inhibitory activity against human acetylcholinesterase (AChE) (IC50=5.52 μM).
    Stemoninine
  • HY-13409B
    SB 242084 monohydrochloride 1260505-34-7 98%
    SB 242084 monohydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 monohydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 monohydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage.
    SB 242084 monohydrochloride
  • HY-134189
    EST73502 1838622-25-5 98%
    EST73502 is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 has antinociceptive activity.
    EST73502
  • HY-134264
    8-Br-2'-O-Me-cAMP 612513-13-0 98%
    8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research.
    8-Br-2'-O-Me-cAMP
  • HY-134361
    ATP-γ-S tetrasodium 88453-52-5 98%
    ATP-γ-S (tetrasodium) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATP-γ-S (tetrasodium) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATP-γ-S (tetrasodium) is active in ATP hydrolysis.
    ATP-γ-S tetrasodium
  • HY-134398
    Kinetin triphosphate 1450894-16-2 98%
    Kinetin triphosphate(6-Fu-ATP; KTP) is an ATP analogue that regulates or enhances kinase function with higher catalytic efficiency than its endogenous substrate, ATP. Kinetin triphosphate can be used in Parkinson's disease research.
    Kinetin triphosphate
  • HY-134562
    PF-06371900 1622291-81-9 98%
    PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor.
    PF-06371900
  • HY-13458A
    Droxidopa hydrochloride 1260173-94-1 98%
    Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder).
    Droxidopa hydrochloride
  • HY-134615
    Mead ethanolamide 169232-04-6 98%
    Mead ethanolamide is an endogenous cannabinoid receptor agonist with Kd values of 753 nM and 1810 nM against CB1 and CB2, respectively.
    Mead ethanolamide
  • HY-134912
    CMPPE 841253-81-4 98%
    CMPPE is a GABAB receptor positive allosteric modulator (PAM) that inhibits alcohol self-administration and reinstatement behavior in rats.
    CMPPE
  • HY-134937
    BC8-15 950385-77-0 98%
    BC8-15 is a PDE inhibitor with IC50 values of 0.28, 0.22, and 6.46 µM for inhibiting PDE8A, PDE4A, and PDE7A, respectively. BC8-15 can enhance steroidogenesis in mouse Leydig cells.
    BC8-15
  • HY-135000
    Decarbamoylsaxitoxin 58911-04-9 98%
    Decarbamoylsaxitoxin is an acid hydrolysis product of saxitoxin. Decarbamoylsaxitoxin is a potent neurotoxin that has a lower potency than saxitoxin .
    Decarbamoylsaxitoxin
  • HY-135034
    UMB68 sodium 581099-89-0 98%
    UMB68 sodium is a selective GHB receptor ligand. UMB68 sodium displaces [3H]NCS-382 with an IC50 of 38 nM in rat cerebrocortical membranes. UMB68 sodium has no significant affinity at GABAB receptors, cannot be metabolized to GABA-active compounds.
    UMB68 sodium
  • HY-135131
    Synthalin hydrochloride 301-15-5 98%
    Synthalin hydrochloride is a K+ channel blocker with neuronal excitability modulating activity. Synthalin hydrochloride has an effect on NMDA-mediated depolarization, possibly through receptor-mediated modulation of L-glutamate and serotonin (5-HT). The use of Synthalin hydrochloride can enhance the understanding of changes in membrane potential of different neurons and help study the role of polyamines in neuronal excitability.
    Synthalin hydrochloride
  • HY-135166
    2-(1-Hydroxypentyl)benzoic acid 380905-48-6 98%
    2-(1-Hydroxypentyl)benzoic acid is a compound being explored for its potential use in the treatment of acute ischemic stroke (AIS).
    2-(1-Hydroxypentyl)benzoic acid
  • HY-135167
    HOCPCA 867178-11-8 98%
    HOCPCA is a compound with neuroprotective activity that improves sensorimotor function in mice after experimental stroke. HOCPCA selectively binds to the CaMKIIα hub domain, modulates signaling of different CaMKII pools, and alleviates abnormal CaMKII signaling after cerebral ischemia. HOCPCA promotes hippocampal neuronal activity and enhances working memory. HOCPCA also normalizes Thr286 autophosphorylation in the cytoplasm after ischemia and downregulates ischemia-specific expression of active CaMKII enzymatic cleavage fragments. HOCPCA binds to the GHB binding site with 27-fold higher affinity than GHB and has good blood-brain barrier penetration ability.
    HOCPCA
  • HY-135204
    Deschloronorketamine hydrochloride 7015-20-5 98%
    Deschloronorketamine hydrochloride is an arylcyclohexylamine and is a metabolite of Deschloroketamine.
    Deschloronorketamine hydrochloride
  • HY-135208
    tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate 916048-02-7 98%
    tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate is an intermediate used in the synthesis of potent DP2 receptor antagonists based on a novel spiro-indolinone compound.
    tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate
  • HY-135222
    MMAI hydrochloride 132980-17-7 98%
    MMAI (5-Methoxy-6-methyl-2-aminoindan) hydrochloride is a selective serotonin releaser that does not produce psychoactive or hallucinogenic effects in the context of drug discrimination in rats. MMAI hydrochloride induces a behavioral syndrome in rats, including hypokinesia with freezing, spinning, Straub tail, flat posture, and reduced sleep time.
    MMAI hydrochloride
  • HY-135228
    GZ4 68312-88-9 98%
    GZ4 is a calcium current inhibitor with direct inhibitory activity on cell surface channels. GZ4 inhibition reverses mechanical hyperalgesia/hyperalgesia in a spinal nerve ligation-induced neuropathic pain model. The mechanism of action of GZ4 is similar to that of gabapentin, but the time course of its biological effects is more rapid, indicating that GZ4 can directly inhibit calcium channel currents.
    GZ4
Cat. No. Product Name / Synonyms Application Reactivity